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1. Introduction
1.1. History, occurrence and use
The discovery of heparin is generally attributed to McLean and 
Howell, although there was considerable debate, not least among 
themselves, concerning priority. Heparin was first commercialised 
in the 1920s despite the observation of side-effects arising, as 
we now know, from impurities. By 1933, Banting and Best had 
developed heparin from bovine liver and this was trialled in Canada 
between 1933 and 1936, culminating in its successful use in humans 
in 1937. During this period, Jorpes in Sweden had been developing 
the purification process and, by 1936, an improved heparin product 
was available. In the 1940s, Moloney and Taylor developed a method 
for mass-producing heparin, which superseded the earlier one. 
Subsequently, heparin was used extensively as an anticoagulant in 
surgery and during dialysis. Later refinement of heparin has included 
the introduction of low molecular weight heparin (LMWH) variants, 
achieved using a variety of depolymerisation techniques. LMWH 
was produced following the discovery that the action of heparin 
via antithrombin (AT) required shorter fragments than its action 
through thrombin (factor IIa) and, by exploiting this selectivity, 
favourable clinical properties could be obtained. It was later found 
that a short (pentasaccharide) sequence within the heparin chains 
provided high affinity binding to AT and high anticoagulant activity. 
This line of enquiry culminated in the production of a synthetic 
pentasaccharide, fondaparinux, which has been commercialised. We 
do not intend to discuss the clinical and biochemical properties of 
these agents here; this has been addressed elsewhere by others far 
better qualified to do so [1–3]. Instead, we will restrict ourselves to 
recent developments (largely since 2010) in the structural analysis 
of heparin, which is itself of importance for several reasons. First, 
the production quality and, indeed, the identification of particular 
processes employed during production (especially of LMWH) can be 
monitored. Second, the natural variation, as well as any potential 
unwanted or unintended structures, can be monitored and the 
overall quality followed. Additionally, the complex question of 
structure-activity relationships, not only between heparin and 
proteins of the blood clotting cascade, but also many other proteins 
[4,5] can be advanced. In recent years, following concerns during the 
1990s about the possibility of contaminating heparin with the agents 
responsible for bovine encephalopathies that led to the widespread 
abandonment of bovine heparin as a pharmaceutical agent, 
commercial heparin has been obtained almost exclusively from pig 
intestinal mucosa, apart from some bovine material, principally in 
South America. However, since the contamination of the heparin 
supply chain with a chemically modified glycosaminoglycan (GAG) 
in 2008 [6], there is renewed interest in diversifying the sources of 
heparin to the extent that bovine sources are now being considered 
for re-introduction into the United States market [7,8].
Heparin is a complex mixture of polysaccharides of the GAG 
class, whose other members include the closely related heparan 
sulfate (HS), as well as chondroitin sulfate (CS), dermatan sulfate 
(DS), keratan sulfate (KS) and hyaluronic acid (HA), and is one of the 
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Heparin, the widely used anticoagulant drug, is unusual among major pharmaceutical agents being 
neither single chemical entity nor a defined mixture of compounds. Its composition, while conforming to 
approximate average disaccharide composition or sulfation levels, exhibits heterogeneity and variability 
depending on the source, as well as its geographical origin. Furthermore, individual polysaccharide chains, 
whose physico-chemical properties are extremely similar, cannot be separated with current state-of-the-
art techniques, presenting a challenge to those interested in the quality control of heparin, in ensuring its 
provenance and safety, and those with an interest in investigating the relationships between its structure 
and biological activity. The review consists of two main sections: The first is the Introduction, comprising 
(i) The History, Occurrence and Use of Heparin and (ii) Approaches to Structure-Activity Relationships. The 
second section is Improved Techniques for Structural Analysis, comprising; (i) Separation and Identification, 
(ii) Spectroscopic Methods, (iii) Enzymatic Approaches and (iv) Other Physico-Chemical Approaches. The ~60 
references cover recent technological advances in the study of heparin structural analysis, largely since 2010.
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most important and widely-used pharmaceutical agents in current 
use. It is employed primarily in situations where the aim is to 
prevent thrombi forming, such as during surgery and blood dialysis. 
In its role as an anticoagulant, its mode of action is via several 
components of the blood-clotting cascade, principally antithrombin 
and thrombin (factor IIa) but, it also exerts action on several other 
components, including factors IX and XI, as well as many other 
proteins. At least some of these interactions with proteins seem 
to arise by virtue of the underlying structural similarity between 
heparin and the naturally occurring cell-surface polysaccharide 
components of proteoglycans, HS [9]. The principles underlying 
the interactions between heparin and some of these proteins, most 
notably AT and thrombin, have been studied extensively, employing 
strategies that first depolymerise the heparin into oligosaccharides, 
isolate the binding saccharide components and then characterise 
them. Using such approaches, the caveats to which have been 
discussed elsewhere [10], the contrasting nature of interactions 
between heparin and AT, or with thrombin, were revealed. This early 
success, which led to the production first of LMWH and then to the 
targeted synthesis of the pentasaccharide with high activity against 
AT, encouraged a similar approach to be employed for the attempted 
isolation of analogous high-affinity oligosaccharides active with 
other proteins. This strategy has almost completely failed, leading 
some to propose an explanation of the anomalous case of AT in 
terms of the experimental methods used and to suggest a general 
property of redundancy regarding the interactions of saccharides 
with proteins [11,12].
1.2. The approach to structure-activity relationships
To attempt to correlate the structure of heparin (and its 
oligosaccharide constituents) with protein binding and activity 
remains the ultimate aim of structure-function studies in this area. 
However, to do so it is now clear that the approach adopted above 
needs to be modified. There are a number of over-arching strategies 
available: One is to fractionate or, ideally, separate to homogeneity 
(using one or several chromatographic techniques) the components 
in a mixture and to determine their structure, then to correlate 
these with binding and activity data, noting the important point 
that binding does not necessarily equate with activity directly. From 
these data, it is then hoped that the factors determining activity will 
become apparent. A complementary approach attempts to conduct 
structural analyses on a mixture or a partially separated mixture, 
about which some detailed structural information is, nevertheless, 
available with the aim of providing some insight into the structural 
features of heparin responsible for activity.
Heparin is unusual among mainstream pharmaceutical agents in 
that it does not consist of a single chemical structure. In fact, the 
situation is even more complex and challenging than this simple 
statement would suggest, because heparin cannot be defined even as 
a mixture of defined substances. The reasons for this are several. In 
the first place, heparin is a polydisperse polysaccharide whose chain 
lengths and their distribution vary, not only in the source material as 
a function of individual animal and geographic location but, also as a 
consequence of subsequent processing. Next, the sequences present 
within heparin samples, while conforming to broad compositions in 
terms of the constituent disaccharides and gross sulfation position 
that allow, for example porcine mucosal heparin to be distinguished 
from bovine mucosal heparin [13], also vary to some extent, leading 
to the property of micro-heterogeneity. Third, the processing and 
treatment of the heparin as it is rendered into its pharmaceutical 
state can also induce some additional structural changes and these 
depend on the process involved but, can also vary between batches, 
even when those processes are deemed to be identical [14].
The overall challenge is therefore two-fold: How to define 
‘heparin’ in the first place? Then; how to relate the structures that 
comprise a heparin sample to its activity? This second part masks 
further major technical obstacles which include; the identification 
of the sequences present within a sample of heparin and its usual 
pre-requisite; how to separate its constituent chains to allow that 
sequencing to take place. It must be stated at the outset that, with 
the present state of technical know-how, both of these procedures 
involve studying oligosaccharide fragments, rather than the full-
length heparin chains and the equivalence of these approaches, 
especially concerning biological activity, has been questioned [10]. 
Much of this review will be devoted to surveying recent technical 
improvements and innovations that address these dual challenges 
or provide methods with which this might be undertaken.
It might also be informative to recall that the relationship 
between heparin oligosaccharide fragments and a very wide range 
of protein-binding events and activities have been found to exhibit 
a degree of redundancy, by which it is meant that several heparin 
oligosaccharide sequences appear able to elicit similar binding or 
activities. This is not to say, however, that all or even most sequences 
exhibit the same activity. A summary of the large body of data 
amassed to date would be that the determining properties seem to 
relate to a combination of charge distribution and conformation but, 
that these properties do not usually relate in any simple way (for 
example, through a straightforward consensus of particular sulfation 
positions or patterns) nor, in many cases, to overall charge density. 
It can be concluded that the physical characteristics of a binding or 
active oligosaccharide, while undoubtedly determined ultimately 
by their sequence and sulfation pattern, are not readily discernible 
experimentally with the present state of the art. Indeed, the 
apparent similarity in behaviour of many heparin oligosaccharides 
at the level of molecular interactions with proteins must serve as a 
warning of the difficulties that are likely to be encountered when 
attempting their separation on the basis of global properties such as 
charge, volume or cross-sectional area. Nevertheless, some notable 
progress has been made employing multi-dimensional approaches, 
many of which will be described below.
Undoubtedly a major step in the analysis of heparin (and other 
GAGs) that has blossomed in recent years is the application of mass 
spectrometry to structure determination. As stated above, this is 
usually dependent on the prior separation of oligosaccharides, 
although the application of ion-trap techniques can contribute to 
alleviating this requirement. Nevertheless, even these advances are 
not without their difficulties; the migration of sulfate groups during 
the ionisation process and the isomeric nature of several of the 
constituent disaccharides (hence of many oligosaccharides) being 
two significant examples. In the following, attempts to improve 
separation and conduct structural analysis, which are frequently 
constituent parts of the same research article, will be treated together.
2. Improved techniques for structural analysis
2.1. Separation and identification
Separation and quantification of heparin oligosaccharides has 
been achieved employing reverse phase, ion-paired high-per for-
mance liquid chromatography (HPLC) combined with electrospray 
quadrupole-time of flight mass spectrometry (Q-TOF), which 
included an amine additive and 1,1,1,3,3,3 hexafluoro-2-propanol 
(HFIP) to improve separation [15]. Heparan sulfate, heparin and 
LMWH-derived disaccharides derivatised with 2-aminoacridone 
(2AA) were separated using reverse-phase HPLC with fluorescence 
detection and electro-spray ionization mass spectrometry (ESI-MS) 
[16]. Disaccharides from heparin, the main tetrasaccharide bearing a 
3-O-sulfate group and unusual oligosaccharides arising from LMWH 
were separated using reverse-phase, ion paired HPLC [17].
A substantial contribution to the analysis of GAGs, applied 
to heparin or with the potential to be applied to heparin, has 
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been made by the group of Linhardt. These have included several 
improved techniques based on combinations of chromatography and 
mass spectrometry, including ultra-high performance (UHP) HPLC 
Q-TOF analysis of LMWH including a profiling of LMWHs in which 
up to 120 oligosaccharides were identified and assigned [18], liquid 
chromatography (LC) tandem MS [19,20], hydrophobic interaction 
liquid chromatography (HILIC) FT MS [21,22], LC-MS analysis of 
oligosaccharides resistant to heparinase II (hII) enzyme digestion 
[23], GAG analysis employing capillary zone electrophoresis-laser 
induced fluorescence (CZE-LIF) with 2AA labelling [24] and 2AA 
labelling for fluorescent detected LC-MS [25]. Finally, a promising 
technique, with the potential to differentiate oligosaccharides with 
the same mass to charge ratios, a long-standing and fundamental 
problem in the field, has been developed [26].
In other work, the effect of the ion-pairing reagent and eluent 
pH on the separation of disaccharide components by reverse phase 
chromatography was investigated and optimum resolution was 
obtained under low pH conditions [27]. Using ultra-performance 
gel permeation chromatography (GPC) combined with Q-TOF MS, 
LMW heparin was fractionated into 70 components and further 
studied using CZE [28]. A mass spectrometry study of disaccharides 
from chemically modified heparins, detected 1,6-anhydro residues 
and demonstrated an unusual periodate cleavage of amino sugar 
residues [29].
Capillary electrophoresis (CE) has been used to conduct a total 
GAG analysis [24]. The numerous methods for separating heparin-
derived oligosaccharides by CE have been reviewed elsewhere [30]. 
Of particular interest is CE under conditions amenable to subsequent 
analysis by MS [31]. One further approach, employing CE that has 
been applied to CS but, which also holds promise for improved 
heparin disaccharide analysis employs fluorescence resonance 
energy transfer (FRET) based on the conjugation of a quantum dot 
(linked via streptavidin) as donor and cyanine-5 (cy5) as acceptor 
[32].
2.2. Spectroscopic methods
One area in which significant advances have been made in recent 
years concerns the study of the 15N nucleus by nuclear magnetic 
resonance (NMR) spectroscopy in GAGs, including heparin and 
model compounds. This aspect of NMR spectroscopy provides 
information that is complementary to other NMR techniques (i.e. 
detecting 1H and 13C) and other structural techniques in general. The 
principal investigators in this field have been the group of Larive, 
who have detected 1H and 15N resonances of the sulfamate (-NHSO3
-) 
group which is situated at position-2 of glucosamine residues, in 
monosaccharides and the pentasaccharide [33,34], then heparin and 
HS [35], going on to study solvent exchange with the N-H proton 
to detect a persistent hydrogen bond between the sulfamate N-H 
proton and the adjacent 3-O-sulfate group in the pentasaccharide 
[36], which has been modelled [37]. They have also pioneered the 
use of long-range 1H-15N correlations on monosaccharides to show 
that the 6-O-sulfate does not significantly affect the environment 
of the nitrogen [38] and have improved the sensitivity of the 
technique [39]. The same group has also employed NMR to follow 
the enzymatic degradation of heparin [40] and have constructed 
a high-sensitivity NMR micro-coil, which allowed minor compo-
nents to be detected, including two previously unreported 
tetrasaccharides from heparin [41]. Advances have also been made 
using ion mobility mass spectrometry [42], electron ionisation (EI) 
ion trap mass spectrometry [43] as well as in improved separation 
of oligosaccharides employing graphitized carbon columns followed 
by ESI-MS [44].
Other notable findings have included the identification of a 
heparin dodecasaccharide containing two antithrombin binding sites 
[45], an antithrombin-binding octasaccharide with an additional 
3-O-sulfated glucosamine residue in the active pentasaccharide [46] 
and the study of the conformation and activity of 1,6-anhydro sugars 
identified in antithrombin-binding octasaccharides [47].
In a distinct set of approaches, NMR statistical correlation 
spectro scopy has been employed to extract structural details 
directly from the heparin mixture, without purification. The tri-
sulfated glucosamine residue has been identified within both the 
conventional pentasaccharide, but also at the non-reducing terminal 
of heparin chains. In addition, IdoA2S residues linked to glucosamine 
6-sulfate (free-amine) adjacent to the linkage region [48] were 
observed. The production of some heparin preparations, such as low 
molecular weight Enoxaparin, the generic form of Lovenox, involves 
the application of base treatment of the benzoyl ester of heparin 
and this basic step can introduce several additional modifications 
into the structure. These include a small amount of epoxide, formed 
between positions -2 and -3 in formerly 2-O-sulfated iduronate 
2-O-sulfate residues [49] and formation of 1,6-anhydro-amino sugars 
(both GlcN and ManN, the latter of which arises from base-catalysed 
epimerisation [50]. All of these modifications, as well as varied 
levels of the linking tetrasaccharide containing fragment, GlcA-
Gal-Gal-Xyl-ser, can be detected in samples of commercial LMWH 
employing a combination of NMR (in this case, using heteronuclear 
single quantum coherence (HSQC) spectra) and multivariate analysis 
techniques of a library of such products [14]. This analysis overlaps 
to some extent with the identification of contaminating species 
within the heparin samples. Indeed, in many respects, the challenge 
of separation and/or distinguising characteristic signals is similar.
The most complete description of oligosaccharides obtained 
from heparin has been achieved by Hricovini, who has combined 
NMR with molecular simulations, studying the effects of solvent 
and counter ions [51], a trisaccharide repeat of heparin [52] and 
most recently, a study of the pentasaccharide employing density 
functional theory (DFT) and NMR, identifying new hydrogen bonds 
[53].
Since heparin carries a substantial negative charge, it can be made 
to migrate in an electric field, which is the basis of electrophoresis 
techniques (gel electrophoresis and forms of CE), which have been 
mentioned above. Under normal conditions there are no, or only 
very few, free amino groups present in the molecules, lending 
the macromolecule an extremely acidic nature and very low pI. 
However, there are certain circumstances in which an increased 
positive charge can be introduced. This can occur either by the 
binding of some cationic species (as was achieved in early work by 
Nader and by Johnson [54,55] or, through the extensive removal 
of N-sulfates and/or N-acetyl groups (both of which are selective 
and reversible by chemical means) to expose free amino groups 
which, under low pH conditions, are protonated, hence, positively 
charged, resulting in zwitterionic species with low net pI. This is 
the basis upon which Holman et al. achieved focusing of heparin 
oligosaccharides using low pH gradient isoelectric focusing (IEF) 
following earlier fractionation by GPC and high performance anion 
exchange chromatography (HPAEC) [56].
2.3. Enzymatic approaches
In a separate line of research, the Liu and Linhardt research 
groups have pioneered the development of enzymatic approaches to 
the enzymatic synthesis of heparin oligosaccharides while, strictly 
speaking, not an analytical technique per se, provides tools (defined 
oligosaccharides) which promise to be of considerable significance 
experimentally as well as serving as analytical standards [57–62].
2.4. Other physico-chemical approaches
The group of Dubin has made important contributions to the 
discussion concerning the nature of interactions between heparin 
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and proteins, arguing against the kind of exquisite specificity 
proposed earlier for the interactions between proteins and heparin 
[63] and, for example, showing that charge-charge interactions 
account for as little as 30% of the free energy of binding [64]. These 
findings resonate with a recent theoretical report stating that 
positively charged amino acids (Arg and Lys) are poor predictors of 
heparin binding sites on protein surfaces, while the uncharged side 
chains of Gln and Asn were posited as important for their ability 
to hydrogen bond [65]. The geographical origin of heparin, which 
is of particular concern in light of problems with provenance, has 
been examined through analysis of stable isotopes, revealing that 
the content of 13C and 18O isotopes provided good overall ability 
to differentiate its origin [66]. The possibility of de-N-sulfation in 
heparin samples, arising from heating and/or exposure to acidic 
conditions or solvents has also been assessed, employing labelling 
of the resultant free amine groups and disaccharide analysis 
employing HILIC MS [21].
We have included these latter miscellaneous findings because, 
they suggest that our view of those features of the heparin chain 
that are currently considered important for protein binding and 
activity need to be continually questioned, and this will influence 
the nature of the information we seek concerning heparin structure 
in the future.
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